189 related articles for article (PubMed ID: 23192276)
1. Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres.
Czyz M; Koprowska K; Sztiller-Sikorska M
Cancer Biol Ther; 2013 Feb; 14(2):135-45. PubMed ID: 23192276
[TBL] [Abstract][Full Text] [Related]
2. Sphere formation and self-renewal capacity of melanoma cells is affected by the microenvironment.
Sztiller-Sikorska M; Koprowska K; Jakubowska J; Zalesna I; Stasiak M; Duechler M; Czyz ME
Melanoma Res; 2012 Jun; 22(3):215-24. PubMed ID: 22495670
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic diversity of patient-derived melanoma populations in stem cell medium.
Sztiller-Sikorska M; Hartman ML; Talar B; Jakubowska J; Zalesna I; Czyz M
Lab Invest; 2015 Jun; 95(6):672-83. PubMed ID: 25867763
[TBL] [Abstract][Full Text] [Related]
4. Parthenolide enhances dacarbazine activity against melanoma cells.
Koprowska K; Hartman ML; Sztiller-Sikorska M; Czyz ME
Anticancer Drugs; 2013 Sep; 24(8):835-45. PubMed ID: 23797801
[TBL] [Abstract][Full Text] [Related]
5. The helicase HAGE prevents interferon-α-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1.
Mathieu MG; Miles AK; Ahmad M; Buczek ME; Pockley AG; Rees RC; Regad T
Cell Death Dis; 2014 Feb; 5(2):e1061. PubMed ID: 24525737
[TBL] [Abstract][Full Text] [Related]
6. Natural compounds' activity against cancer stem-like or fast-cycling melanoma cells.
Sztiller-Sikorska M; Koprowska K; Majchrzak K; Hartman M; Czyz M
PLoS One; 2014; 9(3):e90783. PubMed ID: 24595456
[TBL] [Abstract][Full Text] [Related]
7. Targeting melanoma stem cells with the Vitamin E derivative δ-tocotrienol.
Marzagalli M; Moretti RM; Messi E; Marelli MM; Fontana F; Anastasia A; Bani MR; Beretta G; Limonta P
Sci Rep; 2018 Jan; 8(1):587. PubMed ID: 29330434
[TBL] [Abstract][Full Text] [Related]
8. Identification of cells initiating human melanomas.
Schatton T; Murphy GF; Frank NY; Yamaura K; Waaga-Gasser AM; Gasser M; Zhan Q; Jordan S; Duncan LM; Weishaupt C; Fuhlbrigge RC; Kupper TS; Sayegh MH; Frank MH
Nature; 2008 Jan; 451(7176):345-9. PubMed ID: 18202660
[TBL] [Abstract][Full Text] [Related]
9. ABCB5 maintains melanoma-initiating cells through a proinflammatory cytokine signaling circuit.
Wilson BJ; Saab KR; Ma J; Schatton T; Pütz P; Zhan Q; Murphy GF; Gasser M; Waaga-Gasser AM; Frank NY; Frank MH
Cancer Res; 2014 Aug; 74(15):4196-207. PubMed ID: 24934811
[TBL] [Abstract][Full Text] [Related]
10. Melanoma chemotherapy leads to the selection of ABCB5-expressing cells.
Chartrain M; Riond J; Stennevin A; Vandenberghe I; Gomes B; Lamant L; Meyer N; Gairin JE; Guilbaud N; Annereau JP
PLoS One; 2012; 7(5):e36762. PubMed ID: 22675422
[TBL] [Abstract][Full Text] [Related]
11. Profiling of ABC transporters ABCB5, ABCF2 and nestin-positive stem cells in nevi, in situ and invasive melanoma.
Setia N; Abbas O; Sousa Y; Garb JL; Mahalingam M
Mod Pathol; 2012 Aug; 25(8):1169-75. PubMed ID: 22555176
[TBL] [Abstract][Full Text] [Related]
12. Parthenolide complements the cell death-inducing activity of doxorubicin in melanoma cells.
Wozniak M; Szulawska-Mroczek A; Hartman ML; Nejc D; Czyz M
Anticancer Res; 2013 Aug; 33(8):3205-12. PubMed ID: 23898080
[TBL] [Abstract][Full Text] [Related]
13. Expression of Cell-Surface Marker ABCB5 Causes Characteristic Modifications of Glucose, Amino Acid and Phospholipid Metabolism in the G3361 Melanoma-Initiating Cell Line.
Lutz NW; Banerjee P; Wilson BJ; Ma J; Cozzone PJ; Frank MH
PLoS One; 2016; 11(8):e0161803. PubMed ID: 27560924
[TBL] [Abstract][Full Text] [Related]
14. The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis.
Wouters J; Stas M; Gremeaux L; Govaere O; Van den Broeck A; Maes H; Agostinis P; Roskams T; van den Oord JJ; Vankelecom H
PLoS One; 2013; 8(10):e76550. PubMed ID: 24098529
[TBL] [Abstract][Full Text] [Related]
15. Transient TNF regulates the self-renewing capacity of stem-like label-retaining cells in sphere and skin equivalent models of melanoma.
Ostyn P; El Machhour R; Begard S; Kotecki N; Vandomme J; Flamenco P; Segard P; Masselot B; Formstecher P; Touil Y; Polakowska R
Cell Commun Signal; 2014 Sep; 12():52. PubMed ID: 25223735
[TBL] [Abstract][Full Text] [Related]
16. CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry.
Lai CY; Schwartz BE; Hsu MY
Cancer Res; 2012 Oct; 72(19):5111-8. PubMed ID: 22865455
[TBL] [Abstract][Full Text] [Related]
17. Genetically determined ABCB5 functionality correlates with pigmentation phenotype and melanoma risk.
Lin JY; Zhang M; Schatton T; Wilson BJ; Alloo A; Ma J; Qureshi AA; Frank NY; Han J; Frank MH
Biochem Biophys Res Commun; 2013 Jul; 436(3):536-42. PubMed ID: 23770371
[TBL] [Abstract][Full Text] [Related]
18. A novel spheroid-based co-culture model mimics loss of keratinocyte differentiation, melanoma cell invasion, and drug-induced selection of ABCB5-expressing cells.
Klicks J; Maßlo C; Kluth A; Rudolf R; Hafner M
BMC Cancer; 2019 Apr; 19(1):402. PubMed ID: 31035967
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotype.
Hartman ML; Talar B; Noman MZ; Gajos-Michniewicz A; Chouaib S; Czyz M
PLoS One; 2014; 9(4):e95157. PubMed ID: 24733089
[TBL] [Abstract][Full Text] [Related]
20. Drug resistance is conferred on the model yeast Saccharomyces cerevisiae by expression of full-length melanoma-associated human ATP-binding cassette transporter ABCB5.
Keniya MV; Holmes AR; Niimi M; Lamping E; Gillet JP; Gottesman MM; Cannon RD
Mol Pharm; 2014 Oct; 11(10):3452-62. PubMed ID: 25115303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
